Omega Therapeutics (OMGA) Competitors $0.90 +0.04 (+5.12%) (As of 12:30 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends OMGA vs. INBX, KYTX, BMEA, SOPH, VTYX, FULC, OPT, CYBN, ACRV, and AMRNShould you be buying Omega Therapeutics stock or one of its competitors? The main competitors of Omega Therapeutics include Inhibrx (INBX), Kyverna Therapeutics (KYTX), Biomea Fusion (BMEA), SOPHiA GENETICS (SOPH), Ventyx Biosciences (VTYX), Fulcrum Therapeutics (FULC), Opthea (OPT), Cybin (CYBN), Acrivon Therapeutics (ACRV), and Amarin (AMRN). These companies are all part of the "pharmaceutical products" industry. Omega Therapeutics vs. Inhibrx Kyverna Therapeutics Biomea Fusion SOPHiA GENETICS Ventyx Biosciences Fulcrum Therapeutics Opthea Cybin Acrivon Therapeutics Amarin Inhibrx (NASDAQ:INBX) and Omega Therapeutics (NASDAQ:OMGA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, dividends, valuation and risk. Which has higher valuation & earnings, INBX or OMGA? Omega Therapeutics has higher revenue and earnings than Inhibrx. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInhibrx$1.57M139.13-$154.96MN/AN/AOmega Therapeutics$8.10M6.16-$97.43M-$1.33-0.68 Does the MarketBeat Community prefer INBX or OMGA? Inhibrx received 3 more outperform votes than Omega Therapeutics when rated by MarketBeat users. However, 73.68% of users gave Omega Therapeutics an outperform vote while only 59.62% of users gave Inhibrx an outperform vote. CompanyUnderperformOutperformInhibrxOutperform Votes3159.62% Underperform Votes2140.38% Omega TherapeuticsOutperform Votes2873.68% Underperform Votes1026.32% Do institutionals and insiders hold more shares of INBX or OMGA? 82.5% of Inhibrx shares are held by institutional investors. Comparatively, 97.5% of Omega Therapeutics shares are held by institutional investors. 22.2% of Inhibrx shares are held by insiders. Comparatively, 8.5% of Omega Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media favor INBX or OMGA? In the previous week, Inhibrx had 3 more articles in the media than Omega Therapeutics. MarketBeat recorded 3 mentions for Inhibrx and 0 mentions for Omega Therapeutics. Inhibrx's average media sentiment score of 0.23 beat Omega Therapeutics' score of 0.00 indicating that Inhibrx is being referred to more favorably in the media. Company Overall Sentiment Inhibrx Neutral Omega Therapeutics Neutral Do analysts recommend INBX or OMGA? Omega Therapeutics has a consensus target price of $9.20, suggesting a potential upside of 920.75%. Given Omega Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Omega Therapeutics is more favorable than Inhibrx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inhibrx 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Omega Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Is INBX or OMGA more profitable? Inhibrx has a net margin of 0.00% compared to Omega Therapeutics' net margin of -902.93%. Inhibrx's return on equity of -113.74% beat Omega Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets InhibrxN/A -113.74% -80.56% Omega Therapeutics -902.93%-213.13%-41.24% SummaryOmega Therapeutics beats Inhibrx on 8 of the 15 factors compared between the two stocks. Ad DTIForced out of retirement by these trades You know, I never really intended to get in front of a camera and tell folks about a new market paradigm that I discovered. Even though I have a bright and shiny “resume,” I thought I’d left investing behind forever. And I was more than happy to be a stay-at-home dad… But then I discovered Gamma Pockets… and everything changedMake sure to check out Gamma Pockets HERE while it’s still widely available Get Omega Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OMGA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OMGA vs. The Competition Export to ExcelMetricOmega TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$49.90M$2.98B$5.13B$9.28BDividend YieldN/A1.85%4.81%4.06%P/E Ratio-0.6847.06135.2417.51Price / Sales6.16417.991,174.53134.92Price / CashN/A182.1340.4837.95Price / Book0.863.894.884.94Net Income-$97.43M-$42.03M$118.56M$225.30M7 Day Performance-5.15%-3.70%14.97%-1.11%1 Month Performance17.79%7.37%15.07%7.29%1 Year Performance-63.95%21.33%34.31%23.06% Omega Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OMGAOmega Therapeutics2.316 of 5 stars$0.90+5.1%$9.20+920.7%-65.3%$49.90M$8.10M-0.68120INBXInhibrx1.5779 of 5 stars$15.25-2.9%N/A-48.3%$220.82M$1.63M0.00166Short Interest ↑News CoverageKYTXKyverna Therapeutics2.5531 of 5 stars$5.08+11.6%$25.71+406.2%N/A$219.30M$7.03M0.0096News CoverageBMEABiomea Fusion3.8647 of 5 stars$6.05-0.8%$39.36+550.6%-67.3%$219.25MN/A0.0050Analyst ForecastShort Interest ↑News CoverageSOPHSOPHiA GENETICS2.8722 of 5 stars$3.32-1.8%$6.50+95.8%-24.2%$217.06M$62.37M0.00520Analyst ForecastGap UpVTYXVentyx Biosciences3.2222 of 5 stars$3.06-1.9%$10.00+226.8%+5.3%$216.37MN/A-1.3873News CoverageFULCFulcrum Therapeutics1.8866 of 5 stars$3.99+4.2%$9.33+133.9%-15.8%$215.22M$2.81M0.00100Positive NewsOPTOpthea2.2355 of 5 stars$3.65-1.6%$12.00+228.8%+29.8%$213.16M$120,000.000.008News CoveragePositive NewsGap DownCYBNCybin1.8676 of 5 stars$10.50-2.8%$138.00+1,214.3%N/A$209.90MN/A0.0050ACRVAcrivon Therapeutics1.4082 of 5 stars$6.68+4.0%$23.67+254.3%+57.1%$208.02MN/A0.0058AMRNAmarin0.1611 of 5 stars$0.51+4.8%N/A-43.6%$207.64M$306.91M0.00360 Related Companies and Tools Related Companies Inhibrx Competitors Kyverna Therapeutics Competitors Biomea Fusion Competitors SOPHiA GENETICS Competitors Ventyx Biosciences Competitors Fulcrum Therapeutics Competitors Opthea Competitors Cybin Competitors Acrivon Therapeutics Competitors Amarin Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OMGA) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Omega Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Omega Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OMGA Stock Alerts